Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. "George has been a leader in business development for 30 years. There has been a great deal of industry interest in cytokine p ...